Helping reduce pain and suffering by using chemistry against cancer

For more information call: +1.610.772.3551


JSK Therapeutics (JSKT) is a pre-clinical stage company that aims at the development of novel therapies for cancer. The lead compound that JSKT will bring to market is JS-K, a first-in- class nitric oxide (NO)-generating compound of the arylated diazeniumdiolate class. JS-K is at a preclinical stage of development and has demonstrated activity in animal models of multiple hematologic malignancies and solid tumors. It will be developed initially for the treatment of acute myeloid leukemia and multiple myeloma.